LBRX LB PHARMACEUTICALS INCcompanySEC Filings & Insider Trading Activity 2026
Latest LB PHARMACEUTICALS INC (LBRX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 26, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on March 26, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for LB PHARMACEUTICALS INC (LBRX) (SEC CIK 1691082), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Zachary Prensky retiring from LBRX Board, not standing for reelection at 2026 Annual Meeting; no disagreement with company operations or policies
- • Prensky transitions to consulting role post-departure under amended Transition Agreement (originally dated Nov 26, 2024), effective June 3, 2026
Item 7.01: Regulation FD Disclosure
- • Dr. Lenz appointed to Board of Directors, effective March 9, 2026
- • Board composition change signals potential strategic or scientific advisory shift for LBRX
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Robert A. Lenz appointed to Board Mar 6, 2026; Class I director term expiring 2026 annual meeting; joins Nominating and Corporate Governance Committee
- • Lenz compensation: $45,000 total annual retainer ($40K board + $5K committee) plus initial 20,000-share option grant vesting over 3 years
Recent 8-K FilingsCurrent Reports
AI-powered analysis of LB PHARMACEUTICALS INC (LBRX) 8-K current reports disclosing material events.
Frequently Asked Questions
What are the latest LBRX SEC filings in 2026?
LB PHARMACEUTICALS INC (LBRX) has filed a 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on March 26, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did LBRX file its most recent 10-K annual report?
LB PHARMACEUTICALS INC (LBRX) filed its most recent 10-K annual report on March 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view LBRX 10-Q quarterly reports?
LB PHARMACEUTICALS INC (LBRX)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every LBRX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has LBRX filed recently?
LB PHARMACEUTICALS INC (LBRX)'s most recent 8-K was filed on March 26, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find LBRX insider trading activity (Form 4)?
SignalX aggregates every LBRX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does LBRX file with the SEC?
LB PHARMACEUTICALS INC (LBRX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LBRX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for LB PHARMACEUTICALS INC (LBRX).
What is LBRX's SEC CIK number?
LB PHARMACEUTICALS INC (LBRX)'s SEC CIK (Central Index Key) number is 1691082. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1691082 to look up all LBRX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find LBRX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from LB PHARMACEUTICALS INC (LBRX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of LB PHARMACEUTICALS INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 6+ filings.